

Title	Subcutaneous levetiracetam for seizure management in palliative care patients											
Area where Protocol Applies	SESLHD inpatient settings (including Calvary hospital)											
Indications for use	To maintain control of seizures in a deteriorating and dying patient where no reduction in levels of consciousness is desired, and where the patient is unable to swallow oral medications and IV access is not possible or not desired.											
Important Drug Interactions	Caution is advised with concurrent administration of carbamazepine, methotrexate or phenytoin because of isolated reports of toxicity											
Dose conversion for oral to subcutaneous (subcut) route	A ratio of 1:1 between oral and subcutaneous routes should be used											
Dosage	The usual <u>starting dose</u> is 500-1000mg over 24 hours via continuous subcutaneous infusion (CSCI) titrated to effect.											
Hepatic Impairment	No dose adjustment is required with mild to moderate hepatic impairment. Care with hepatorenal syndrome - dose based on renal function (see below)											
Renal Impairment	Dose adjustment with renal impairment:											
	<table border="1"> <thead> <tr> <th>Creatinine Clearance (ml/min)</th> <th>Usual maintenance dose</th> </tr> </thead> <tbody> <tr> <td>> 80</td> <td>1000 – 3000mg over 24 hours</td> </tr> <tr> <td>50-79</td> <td>1000 – 2000mg over 24 hours</td> </tr> <tr> <td>30-49</td> <td>500 – 1500mg over 24 hours</td> </tr> <tr> <td>< 30</td> <td>500 – 1000mg over 24 hours</td> </tr> </tbody> </table>	Creatinine Clearance (ml/min)	Usual maintenance dose	> 80	1000 – 3000mg over 24 hours	50-79	1000 – 2000mg over 24 hours	30-49	500 – 1500mg over 24 hours	< 30	500 – 1000mg over 24 hours	
Creatinine Clearance (ml/min)	Usual maintenance dose											
> 80	1000 – 3000mg over 24 hours											
50-79	1000 – 2000mg over 24 hours											
30-49	500 – 1500mg over 24 hours											
< 30	500 – 1000mg over 24 hours											
Preparations	Levetiracetam 100mg/mL concentrate solution for infusion. Each 5mL vial contains 500mg levetiracetam.											
Administration	Levetiracetam should be diluted as much as is practical to avoid infusion site irritation. Maximum 1600mg in 20mL syringe. Maximum 2400mg in 30mL syringe. (30mL syringes available via Palliative Care Team) If higher doses are required (maximum 3000mg) administer in 100mL sodium chloride 0.9% via an infusion pump. Contact Palliative Care Team for advice.											

Diluents	Dilute with water for injection for administration via syringe driver. Doses >2400mg must be diluted in 100mL sodium chloride 0.9% (see above)
Drug Compatibility	Levetiracetam should not be mixed with any other medication due to lack of robust compatibility data.
Undesirable effects	Very common (>10%): fatigue, drowsiness, headache, injection site irritation Common (<10%, >1%): ataxia, hyperkinesia, tremor, dizziness, diplopia, blurred vision, amnesia, behavioural disturbances, depression, insomnia, anorexia, abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, myalgia, rash, pruritus, thrombocytopenia. See MIMS for full list.
Monitoring requirements	Monitor seizure activity and titrate dose accordingly. Monitor for injection site reactions. Perform 4 hourly infusion site checks as per Subcutaneous Syringe Driver inpatient management form SES130.021.
Management of complications	Any seizure activity seen during subcutaneous levetiracetam infusion should be managed with benzodiazepines, then specialist advice sought.
Practice Points	Administer alone in a separate syringe driver or infusion pump. Ensure dose adjustment is made for renal impairment. Benzodiazepines remain the first line management for prolonged seizure or status epilepticus. Seizure control should be achievable with appropriate dose adjustment, but if a seizure cannot be controlled or status epilepticus develops seek specialist advice. Additional antiepileptic or anaesthetic agents may be needed. Refer to eTG Palliative Care: 'Seizures in palliative care: overview' for more information
Basis of Protocol/Guideline (including sources of evidence, references)	Palliative Care Formulary 7th Ed, 2020 p 306-309 Therapeutic Guidelines – Palliative Care, eTG, July 2018 Dickman A, Schneider J. The syringe driver: continuous subcutaneous in palliative care. Oxford University Press; 2016 Our Lady's Hospice & Care Service, Harold Cross, Dublin Ireland, 2016: https://olh.ie/wp-

	content/uploads/2019/01/Levetiracetam-in-a-Syringe-Pump-November-2018.pdf
Consultation	St George Palliative Care Team SESLHD Palliative Care working party Dr Caitlin Sheehan, Specialist Palliative Care, SESLHD southern sector

AUTHORISATION	
Author (Name)	Dr Jan Maree Davis
Position	Medical Director, Palliative Care
Department	SESLHD Southern Sector
Department Contact (for ongoing maintenance of Protocol/Guideline)	JanMaree.davis@health.nsw.gov.au
GOVERNANCE	
Enactment date/ Renewal date (NB delete as appropriate)	November 2020 December 2023
Expiry date: (maximum 36 months from date of original approval)	December 2026
Ratification date by SESLHD QUM Committee	7 December 2023
Chairperson, QUM Committee	Dr John Shephard
Version Number	2.0